Litigation Details for Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. (D. Del. 2022)

Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. (D. Del. 2022)

Docket		Date Filed	2022-10-24
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Defendant	Referred To
Patents	10,335,462; 8,101,659; 8,679,069
Link to Docket	External link to docket

Biologic Drugs cited in Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc.

Details for Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2024-08-20	257	Redacted Document	5. In the Inter Partes Review of U.S. Patent 10,335,462 (Mylan Pharmaceuticals, Inc., et al. v. Novo…worldwide.7 9. U.S. Patent No. 8,101,659 (“the ’659 patent”) issued on January 24, 2012, and…conditions, among others.8 U.S. Patent No. 11,096,918 (“the ’918 patent”) issued on August 24, 2021, …Novartis combination patent appeal, or ongoing litigations involving other patents, may be at risk of …on the ‘659 patent, which was later held to be invalid. As Novartis notes, the ‘918 Patent is not eligible	External link to document
2024-08-20	270	Redacted Document	.S. Patent No. 8,101,659 (“the ’659 patent”) against MSN, and that the validity of the ’659 patent …659 and ’918 Patents and Nexus 45. Novartis’s counsel informs me that U.S. Patent 8,101,659 (“the ’659…659 patent. Novartis’s counsel has also informed me that Novartis has asserted U.S. Patent No. …918 patent”) against MSN, and that the infringement and validity of the ’918 patent will be tried… Novartis noted that loss of patent exclusivity for one or more patented products – such as Entresto	External link to document